Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...166167168169170171172173174175176...208209»
  • ||||||||||  AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
    Trial completion:  A Trial of SHR6390 in Healthy Caucasian Volunteers (clinicaltrials.gov) -  Oct 1, 2020   
    P1,  N=36, Completed, 
    Not yet recruiting --> Recruiting Active, not recruiting --> Completed
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Review, Journal:  Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target? (Pubmed Central) -  Sep 30, 2020   
    We found that TKIs with promising therapeutic effect for osteosarcoma include apatinib, cabozantinib, lenvatinib, regorafenib, and sorafenib...It is necessary to inhibit several relevant RTKs simultaneously to achieve a breakthrough in osteosarcoma treatment. This review provides comprehensive information on TKI targets relevant in osteosarcoma treatment, and it will be useful for further research in this field.
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Trial completion date, Trial initiation date, Trial primary completion date:  PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery (clinicaltrials.gov) -  Sep 28, 2020   
    P2,  N=65, Recruiting, 
    Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2020 --> Dec 2020 Trial completion date: Dec 2022 --> Feb 2024 | Initiation date: Feb 2020 --> Aug 2020 | Trial primary completion date: Dec 2021 --> Aug 2022
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date:  Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma (clinicaltrials.gov) -  Sep 28, 2020   
    P2,  N=51, Recruiting, 
    Trial completion date: Dec 2022 --> Feb 2024 | Initiation date: Feb 2020 --> Aug 2020 | Trial primary completion date: Dec 2021 --> Aug 2022 Not yet recruiting --> Recruiting | Trial completion date: Oct 2022 --> Dec 2022 | Initiation date: Nov 2019 --> May 2020 | Trial primary completion date: Jan 2022 --> May 2022
  • ||||||||||  famitinib (SHR 1020) / Jiangsu Hengrui Pharma
    Trial completion:  A Drug-drug Interaction Trial to Evaluate the Pharmacokinetics Effect of Rifampicin on Famitinib (clinicaltrials.gov) -  Sep 28, 2020   
    P1,  N=21, Completed, 
    Not yet recruiting --> Recruiting | Trial completion date: Oct 2022 --> Dec 2022 | Initiation date: Nov 2019 --> May 2020 | Trial primary completion date: Jan 2022 --> May 2022 Recruiting --> Completed
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Journal:  Supramolecular Engineering of Molecular Inhibitors in an Adaptive Cytotoxic Nanoparticle for Synergistic Cancer Therapy. (Pubmed Central) -  Sep 27, 2020   
    In this study, we developed a simple and broadly applicable strategy in which ultrastable cytotoxic nanoparticles with an established excellent antitumor efficacy and π-rich inner core structure supramolecularly stabilized the antiangiogenic molecular inhibitor apatinib to create a synergistic drug delivery system (termed sTKI-pSN38)...Interestingly, sTKI-pSN38 treatment alleviated intratumoral hypoxia, which could contribute to impaired tumor metastasis and reduced drug resistance. Collectively, this nanotherapeutic platform offers a new strategy for cancer therapy by simply engineering a drug cocktail in conventional nanoparticles and by enabling the spatiotemporal modulation of drug release to enhance the synergy of the combined drugs.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Clinical, P2 data, Clinical Trial,Phase II, Journal:  Apatinib in patients with advanced chordoma: a single-arm, single-centre, phase 2 study. (Pubmed Central) -  Sep 25, 2020   
    To our knowledge, this is the first trial of apatinib for the treatment of advanced chordoma. Apatinib shows promising activity and manageable toxicity and thus might be an option for the treatment of advanced chordoma.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Clinical, Journal:  Antiangiogenic therapy for Wilms tumor in an adult and literature review. (Pubmed Central) -  Sep 24, 2020   
    Here, we report a case of Wilms tumor in a 24-year-old woman who was effectively treated with apatinib, a small-molecule inhibitor of vascular endothelial growth factor receptor-2...Starting with this case, we reviewed the features of Wilms tumors in adults and its treatment with antiangiogenic therapy. The information in this review could provide a novel approach to treating adults with Wilms tumors.
  • ||||||||||  AiRuiKa (camrelizumab) / Incyte
    [VIRTUAL] TREATMENT RELATED ADVERSE EVENTS PREDICT BETTER PROGRESSION FREE SURVIVAL FOR HCC UNDERWENT ANTI-PD-1 THERAPY () -  Sep 24, 2020 - Abstract #ILCA2020ILCA_217;    
    TRAEs that occurred in more than 10% of patients were reactive capillary hemangiomas in 15 patients (88.2% in patients received Camrelizumab, while 32.6% in all patients), liver dysfunction in 15(32.6%) patients, thyroid dysfunction in 9(19.6%) patients, rash in 6(13%) patients, amylase increase in 5(10.9%) patients, hemocytopenia in 5(10.9%) patients... Treatment related adverse events and vascular invasion were independent prognostic factors for PFS in HCC underwent anti-PD-1 therapy.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, Nexavar (sorafenib) / Bayer, Amgen
    Clinical, Journal:  Apatinib versus sorafenib in patients with advanced hepatocellular carcinoma: a preliminary study. (Pubmed Central) -  Sep 23, 2020   
    The most common any-grade adverse events in the apatinib and sorafenib groups were hand and foot syndrome (53.8% vs. 50%), hypertension (50% vs. 19.6%), diarrhea (34.6% vs. 28.3%), and elevated transaminase (57.7% vs. 63%). Compared with sorafenib, apatinib yielded comparable PFS and OS, and even better ORR, in patients with advanced HCC.
  • ||||||||||  SHR-1819 / Jiangsu Hengrui Pharma
    New P1 trial:  A Trial of SHR-1819 in Healthy Subjects (clinicaltrials.gov) -  Sep 22, 2020   
    P1,  N=42, Not yet recruiting, 
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Clinical, Journal:  Apatinib, combined with chemotherapy or alone is effective in treating angiosarcoma: a case report. (Pubmed Central) -  Sep 21, 2020   
    The progression-free survival of the primary lesion with KRAS V14I and RBM10 E119D mutations (10 months) was shorter than that of the brain without the mutation ( ≥ 12 months). Although it is not clear whether the KRAS V14I and RBM10 E119D mutations are the main factors that impact the effect of apatinib treatment or not, the results of this study will provide valuable clues for relevant follow-up basic and clinical studies.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Clinical, Journal, Combination therapy, Monotherapy:  Apatinib monotherapy or combination therapy for non-small cell lung cancer patients with brain metastases. (Pubmed Central) -  Sep 21, 2020   
    Treatment-related toxicities were tolerable including grade 1/2 hypertension, hand and foot syndrome, fatigue, nausea, liver dysfunction, myelosuppression, skin rash and palpitation. In conclusion, apatinib exhibited highly activity and good tolerance for NSCLC patients with brain metastasis and it might become a potential choice for metastatic brain tumors in NSCLC patients.